-
Fighter. Hero. Cancer-stricken. The words and metaphors people use to talk about cancer often feel worlds apart from any other disease. But how far does it go? Do words matter?
CancerDisease AwarenessLiving With DiseaseOncology -
Basel, February 16, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1. Benefits are most clearly evident in…Reimagine MedicineNeuroscienceMedical InnovationsLiving With Disease
-
One patient’s story reveals the hidden obstacles to better health – and opportunities to help clear them.
Access to HealthcareDisease AwarenessGenetic DiseaseLiving With DiseasePatient Voices -
It’s time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.CancerLiving With DiseaseOncologyPatient VoicesSocial Commitment
-
AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1Reimagine MedicineNovartis Gene TherapiesLiving With Disease
-
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular AtrophyReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular AtrophyReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Proposed Public Offering of Common StockReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Pricing of Public Offering of Common StockReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three PatientsReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating ResultsReimagine MedicineNovartis Gene TherapiesLiving With Disease